• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

    1/11/23 1:00:00 PM ET
    $AEZS
    $AIM
    $AMAO
    $AREC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AEZS alert in real time by email

    - Live video webcast presentations with participating companies -

    FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. As part of the virtual event, participating companies will provide a corporate presentation.

    The schedule for the event is as follows:

    Tuesday, January 17, 2023

    • 9:00 AM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - WEBCAST
    • 10:00 AM ET: Xenetic Biosciences, Inc. (NASDAQ:XBIO) - WEBCAST
    • 11:00 AM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - WEBCAST
    • 1:00 PM ET: Vallon Pharmaceuticals, Inc. (NASDAQ:VLON)/GRI Bio (Private) - WEBCAST
    • 2:00 PM ET: Novan, Inc. (NASDAQ:NOVN) - WEBCAST
    • 3:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - WEBCAST
    • 4:00 PM ET: American Resources Corporation (NASDAQ:AREC) - WEBCAST

    Wednesday, January 18, 2023

    • 10:00 AM ET: CNS Pharmaceuticals Inc. (NASDAQ:CNSP) - WEBCAST
    • 11:00 AM ET:AIM ImmunoTech Inc. (NYSE:AIM) - WEBCAST
    • 1:00 PM ET: Panavance Therapeutics Inc. (Private) - WEBCAST
    • 2:00 PM ET: ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) -WEBCAST
    • 3:00 PM ET: Ceapro, Inc. (TSXV:CZO, OTCQX:CRPOF) - WEBCAST
    • 4:00 PM ET: iTolerance, Inc. (Private) - WEBCAST

    Thursday, January 19, 2023

    • 10:00 AM ET: Adolore Biotherapeutics, Inc. (Private) - WEBCAST
    • 11:00 AM ET: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) - WEBCAST
    • 1:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - WEBCAST
    • 2:00 PM ET: American Acquisition Opportunity Inc. (NASDAQ:AMAO) - WEBCAST
    • 3:00 PM ET: Aeterna Zentaris Inc. (NASDAQ:AEZS, TSX:AEZS) - WEBCAST
    • 4:00 PM ET: SurgePays, Inc. (NASDAQ:SURG) - WEBCAST

    About JTC Team

    JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/734876/JTC-Team-to-Host-the-Virtual-Investor-2023-Companies-to-Watch-Event-on-January-17th-18th-and-19th

    Get the next $AEZS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEZS
    $AIM
    $AMAO
    $AREC

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    American Resources Corporation
    $AREC
    10/20/2025Outperform
    William Blair
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    More analyst ratings

    $AEZS
    $AIM
    $AMAO
    $AREC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree

    3/18/26 10:41:39 AM ET
    $AIM
    $ARTL
    $YYGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Professional Services

    AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

    OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company's proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039. The allowed claims in

    3/18/26 8:36:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Moleculin to Present at 38th Annual ROTH Conference

    – Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it will participate in a fireside chat at the 38th Annual ROTH Conference being held March 22-24, 2026 in Dana Point, CA. Details of the fireside chat presentation are as follows: Date and Time: Tuesday, March 24, 2026 at 12:00-12:25 PM PTLocation: BROWN - HEALTHCARE - VIRTUAL (SUITE 1051)Presenters: Walter Klemp, Founder, President, Chairman & CEO; Jon Foster, EVP & CFO Registration Link: Here Investors interested in arrang

    3/17/26 9:05:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Equels Thomas K converted options into 25,000 shares, increasing direct ownership by 64% to 63,922 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/16/26 5:30:41 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chemerow David I. converted options into 25,000 shares, increasing direct ownership by 727% to 28,441 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    3/16/26 5:30:12 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Duhay Francis sold $1,613 worth of shares (140 units at $11.52), decreasing direct ownership by 5% to 2,502 units (SEC Form 4)

    4 - enVVeno Medical Corp (0001661053) (Issuer)

    3/13/26 4:05:09 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    SEC Filings

    View All

    Outlook Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    3/16/26 9:00:28 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    American Resources Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - American Resources Corp (0001590715) (Filer)

    3/13/26 8:30:33 AM ET
    $AREC
    Coal Mining
    Energy

    Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)

    3/13/26 8:00:27 AM ET
    $XBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director May David Allen bought $61,647 worth of Shares of Common Stock (38,422 units at $1.60), increasing direct ownership by 32% to 158,116 units (SEC Form 4)

    4 - SurgePays, Inc. (0001392694) (Issuer)

    12/11/25 9:37:54 PM ET
    $SURG
    Advertising
    Consumer Discretionary

    $AEZS
    $AIM
    $AMAO
    $AREC
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEZS
    $AIM
    $AMAO
    $AREC
    Financials

    Live finance-specific insights

    View All

    AIM ImmunoTech Announces Stock Dividend

    OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will

    12/30/25 5:10:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

    ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This compares with net loss attributable to common stockholders of $75.4 million, or $4.06 per basic and diluted share, and no revenue for the prior year.

    12/19/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SurgePays Revenue for the Third Quarter 2025 Increases 292% Year-Over-Year and 62% Sequentially

    Third quarter 2025 revenue totaled approximately $18.7 million, an increase of 292% year-over-year and 62% sequentially Company is reiterating revenue guidance for 2026 of $225 million Conference call today at 5:00 p.m. ET BARTLETT, Tenn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- SurgePays, Inc. (NASDAQ:SURG) ("SurgePays" or the "Company"), a wireless and fintech technology company connecting subprime and underserved consumers to essential mobile and financial services, today announced revenue growth of 292% year-over-year and 62% sequentially to $18.7 million for the third quarter ended September 30, 2025. The Company is reiterating revenue guidance of $225 million for 2026. "The 2025 third

    11/12/25 9:20:00 AM ET
    $SURG
    Advertising
    Consumer Discretionary

    $AEZS
    $AIM
    $AMAO
    $AREC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care